Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,711 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19.
Chen P, Datta G, Grace Li Y, Chien J, Price K, Chigutsa E, Brown-Augsburger P, Poorbaugh J, Fill J, Benschop RJ, Rouphael N, Kay A, Mulligan MJ, Saxena A, Fischer WA, Dougan M, Klekotka P, Nirula A, Benson C. Chen P, et al. Among authors: saxena a. Clin Pharmacol Ther. 2021 Dec;110(6):1467-1477. doi: 10.1002/cpt.2405. Epub 2021 Oct 16. Clin Pharmacol Ther. 2021. PMID: 34455583 Free PMC article. Clinical Trial.
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination.
Izmirly PM, Kim MY, Samanovic M, Fernandez-Ruiz R, Ohana S, Deonaraine KK, Engel AJ, Masson M, Xie X, Cornelius AR, Herati RS, Haberman RH, Scher JU, Guttmann A, Blank RB, Plotz B, Haj-Ali M, Banbury B, Stream S, Hasan G, Ho G, Rackoff P, Blazer AD, Tseng CE, Belmont HM, Saxena A, Mulligan MJ, Clancy RM, Buyon JP. Izmirly PM, et al. Among authors: saxena a. Arthritis Rheumatol. 2022 Feb;74(2):284-294. doi: 10.1002/art.41937. Epub 2021 Dec 28. Arthritis Rheumatol. 2022. PMID: 34347939 Free PMC article.
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease.
Haberman RH, Um S, Axelrad JE, Blank RB, Uddin Z, Catron S, Neimann AL, Mulligan MJ, Herat RS, Hong SJ, Chang S, Myrtaj A, Ghiasian G, Izmirly PM, Saxena A, Solomon G, Azar N, Samuels J, Golden BD, Rackoff P, Adhikari S, Hudesman DP, Scher JU; SAGA investigators. Haberman RH, et al. Among authors: saxena a. Lancet Rheumatol. 2022 Jun;4(6):e384-e387. doi: 10.1016/S2665-9913(22)00069-8. Epub 2022 Apr 1. Lancet Rheumatol. 2022. PMID: 35403000 Free PMC article. No abstract available.
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF 3rd, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. Atisha-Fregoso Y, et al. Among authors: saxena a. Arthritis Rheumatol. 2021 Jan;73(1):121-131. doi: 10.1002/art.41466. Epub 2020 Dec 1. Arthritis Rheumatol. 2021. PMID: 32755035 Free PMC article. Clinical Trial.
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B. Ginzler E, et al. Among authors: saxena a. Arthritis Rheumatol. 2022 Jan;74(1):112-123. doi: 10.1002/art.41900. Epub 2021 Dec 9. Arthritis Rheumatol. 2022. PMID: 34164944 Free PMC article. Clinical Trial.
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Furie R, et al. Among authors: saxena a. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180. N Engl J Med. 2020. PMID: 32937045 Clinical Trial.
Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City.
Saxena A, Engel AJ, Banbury B, Hasan G, Fraser N, Zaminski D, Masson M, Haberman RH, Scher JU, Ho G, Law J, Rackoff P, Tseng CE, Belmont HM, Clancy RM, Buyon JP, Izmirly PM. Saxena A, et al. Lancet Rheumatol. 2022 Sep;4(9):e582-e585. doi: 10.1016/S2665-9913(22)00190-4. Epub 2022 Jul 12. Lancet Rheumatol. 2022. PMID: 35856060 Free PMC article. No abstract available.
3,711 results